Pfizer’s All-Comers CRPC Dream For Talzenna Quashed For Lack Of Biomarker-Negative Rigor

 
• By Bridget Silverman

The lack of a formal analysis of efficacy in castration-resistant prostate cancer patients without HRR mutations doomed Pfizer’s Talzenna at the US FDA's Oncologic Drugs Advisory Committee, as FDA oncology chief Richard Pazdur says chance cannot be ruled out.

Pfizer's analysis of the TALAPRO-2 trial is like "somebody shooting an arrow at the wall and then painting a target around it," the FDA's Richard Pazdur said. (Shutterstock)

More from US Advisory Committees

More from Geography